{
  "resourceType": "MedicationKnowledge",
  "id": "bevacizumab",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/MedicationKnowledge"
    ]
  },
  "status": "active",
  "code": {
    "coding": [
      {
        "system": "https://twtxgnn.yao.care/drugs",
        "code": "bevacizumab",
        "display": "Bevacizumab"
      }
    ],
    "text": "Bevacizumab"
  },
  "intendedJurisdiction": [
    {
      "coding": [
        {
          "system": "urn:iso:std:iso:3166",
          "code": "TW",
          "display": "Taiwan"
        }
      ]
    }
  ],
  "extension": [
    {
      "url": "https://twtxgnn.yao.care/fhir/StructureDefinition/evidence-level",
      "valueCode": "L1"
    }
  ],
  "indicationGuideline": [
    {
      "indication": [
        {
          "reference": {
            "display": "轉移性大腸直腸癌(mCRC)\r\n與含有5-fluorouracil為基礎的化學療法合併使用，可以作為..."
          }
        }
      ]
    }
  ]
}